This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/3/2022
Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference call to discuss the company's operations and first quarter 2022 financial results. My name is Sarah and I'll be your operator for today's call. At this time, all participants are in listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at Infinity's request. Now I would like to introduce your host for today's call, Jane Goffman. Please go ahead.
Thank you, Sarah, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review of our first quarter 2022 financial results and company highlights. On the call with me today are Adeline Perkins, Chief Executive Officer and Chair, Larry Block, President, and Robert Alaria, Jr., Chief Medical Officer. We'll open up the call for Q&A following our remarks. The press release issued today details our results and is available on our website at infi.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections. Our actual results may differ materially from what we project today. due to a number of important factors, including the considerations described in the risk factors section of our annual report on Form 10-K for 2021, and in other filings we make with the FCC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. Now, I'd like to turn the call over to Adeline.
Thanks, Jane. And thank you to everyone for joining us today to review Infinity's first quarter 2022 progress. As we discussed on our most recent call just five weeks ago, 2022 is an execution year in which we are focused on expanding the clinical evaluation of aganalysib and additional solid tumor indications and establishing the best path forward to maximize the value of aganalysib for patients and shareholders. We are aggressively advancing the development of aganalysib including the initiation of our first registration trial, MERIO4, in frontline metastatic triple negative breast cancer, or TNBC, by year end. In parallel, we are also planning to initiate our platform program with MERIOP on a rolling basis in the third quarter. We also expect updates from the metastatic TNBC, urothelial cancer, renal cell cancer, and squamous cell cancer of the head and neck trials later in the year. In addition, given the promising future of aganalysib as a first in class drug across multiple solid tumor indications, we are currently evaluating different options, including potential strategic partnerships to access additional human and financial resources, as well as combination drug partners to maximize the opportunity for aganalysib in novel combinations and multiple indications. I'll now turn the call over to Rob to review the studies we are initiating this year as well as potential future development paths.
You're reading a preview of the INFI Q1 2022 earnings call.
Free account.
